AmSurg
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict AmSurg's revenues will grow 15.3% and EPS will grow 16.7%.
The average estimate for revenue is $226.0 million. On the bottom line, the average EPS estimate is $0.49.
Revenue details
Last quarter, AmSurg reported revenue of $231.6 million. GAAP reported sales were 23% higher than the prior-year quarter's $187.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
Last quarter, non-GAAP EPS came in at $0.51. GAAP EPS of $0.49 for Q2 were 32% higher than the prior-year quarter's $0.37 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Recent performance
For the preceding quarter, gross margin was 55.0%, 180 basis points worse than the prior-year quarter. Operating margin was 30.8%, 170 basis points worse than the prior-year quarter. Net margin was 6.7%, 50 basis points better than the prior-year quarter.
Looking ahead
The full year's average estimate for revenue is $925.9 million. The average EPS estimate is $2.01.
Investor sentiment
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 136 members out of 145 rating the stock outperform, and nine members rating it underperform. Among 43 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 39 give AmSurg a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on AmSurg is hold, with an average price target of $28.29.
- Add AmSurg to My Watchlist.